These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28522196)

  • 41. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
    Bajaj HS; Zinman B
    Physiology (Bethesda); 2018 May; 33(3):197-210. PubMed ID: 29638185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Which antidiabetic agent in a patient with type 2 diabetes and heart failure ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Sep; 72(9):423-428. PubMed ID: 28892319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
    Khunti K; Knighton P; Zaccardi F; Bakhai C; Barron E; Holman N; Kar P; Meace C; Sattar N; Sharp S; Wareham NJ; Weaver A; Woch E; Young B; Valabhji J
    Lancet Diabetes Endocrinol; 2021 May; 9(5):293-303. PubMed ID: 33798464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.
    Schernthaner G; Schernthaner GH
    Herz; 2016 May; 41(3):208-16. PubMed ID: 27071968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Classification of non-insulin glucose lowering drugs.
    Kalra S
    J Pak Med Assoc; 2016 Nov; 66(11):1497-1498. PubMed ID: 27812078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Type 2 diabetes mellitus and heart failure].
    Linhart A; Bělohlávek J
    Vnitr Lek; 2016; 62(7-8):592-7. PubMed ID: 27627083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
    Bell DSH; Goncalves E
    Diabetes Obes Metab; 2019 Feb; 21(2):210-217. PubMed ID: 30144274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Extended indications for antidiabetic agents with cardio-renal protection in updated international recommendations for themanagement of at risk patients with type2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2020 Apr; 75(4):233-239. PubMed ID: 32267111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view.
    Fuentes B
    Med Clin (Barc); 2018 Apr; 150(7):275-281. PubMed ID: 29096968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.
    Al-Mashhadi Z; Viggers R; Fuglsang-Nielsen R; de Vries F; van den Bergh JP; Harsløf T; Langdahl B; Gregersen S; Starup-Linde J
    Curr Osteoporos Rep; 2020 Dec; 18(6):737-758. PubMed ID: 33165875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of glucose-lowering agents on ischemic stroke.
    Avgerinos K; Tziomalos K
    World J Diabetes; 2017 Jun; 8(6):270-277. PubMed ID: 28694927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Abdul-Ghani M; DeFronzo RA
    Expert Opin Pharmacother; 2021 Nov; 22(16):2113-2125. PubMed ID: 34435523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Part Six: Antidiabetic Medication Benefits Beyond Glucose Lowering in Older People.
    Pogge EK; Early NK
    Sr Care Pharm; 2022 Oct; 37(10):477-487. PubMed ID: 36171669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.
    Fuentes B; Amaro S; Alonso de Leciñana M; Arenillas JF; Ayo-Martín O; Castellanos M; Freijo M; García-Pastor A; Gomis M; Gómez Choco M; López-Cancio E; Martínez Sánchez P; Morales A; Palacio-Portilla EJ; Rodríguez-Yáñez M; Roquer J; Segura T; Serena J; Vivancos-Mora J;
    Neurologia (Engl Ed); 2021 May; 36(4):305-323. PubMed ID: 32981775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antidiabetic therapies and Alzheimer disease.
    Bendlin BB
    Dialogues Clin Neurosci; 2019 Mar; 21(1):83-91. PubMed ID: 31607783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diabetes and Cancer.
    Holden SE
    Endocr Dev; 2016; 31():135-45. PubMed ID: 26824829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
    Cullinane PW; de Pablo Fernandez E; König A; Outeiro TF; Jaunmuktane Z; Warner TT
    Mov Disord; 2023 Feb; 38(2):162-177. PubMed ID: 36567671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
    Ferrari F; Moretti A; Villa RF
    Neural Regen Res; 2022 Feb; 17(2):292-299. PubMed ID: 34269190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.
    Laeeq T; Ahmed M; Sattar H; Zeeshan MH; Ali MB
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.